What should a regulatory information management (RIM) system offer to support global submissions planning? A RIM system supports global submissions planning by centralizing region-specific requirements, agency correspondence, and real-time submission status in one system — replacing the spreadsheets, inboxes, and shared drives that break down once a program spans more than one regulatory region. The core capabilities to look for are multi-region requirement mapping, correspondence and commitment tracking by agency, and live status visibility across every active submission.
Once a sponsor moves beyond a single-region strategy — say, filing with the FDA and then, in parallel or shortly after, the EMA, Health Canada, or Japan's PMDA — "submissions planning" stops being one task and becomes several running at once:
None of this is unique to large pharma. The FDA and its international counterparts have formally recognized the trend toward simultaneous multi-region development: ICH's E17 guideline, General Principles for Planning and Design of Multi-Regional Clinical Trials — finalized by FDA's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research in July 2018 — exists specifically because "the increasing globalization of drug development" made it necessary for regulators across regions to accept a single, well-designed program as evidence, rather than forcing sponsors to run the same trial over again in every market [1]. The regulatory expectation to plan across regions from the start is already established; the operational question is what system a lean regulatory team uses to actually execute that plan.
A tracking spreadsheet and a shared inbox can carry a single-region regulatory team surprisingly far. They stop working once submissions planning goes global, for a few concrete reasons: no single spreadsheet row can hold every region's dossier requirements without becoming unreadable; email threads with different agencies live in different inboxes, so nothing forces a commitment made to the EMA to stay linked to the document that fulfilled it; and status has to be manually re-typed into a deck or another spreadsheet every time someone outside Regulatory asks for an update. None of this is a discipline problem — it's what happens when the number of regions, agencies, and simultaneous submissions outgrows what a general-purpose tool was built to track.
FDA's own warning letters document what that breakdown looks like in practice when a commitment slips through an inadequate tracking process. In a 2017 warning letter to Vertical Pharmaceuticals, FDA cited three 15-day Alert reports for adverse drug experiences that were submitted 50, 672, and 913 days late, plus three missed annual Periodic Adverse Drug Experience Reports and at least 25 missed non-15-day Alert reports — all traced back to the firm lacking adequate written procedures for evaluating and routing incoming reports to the right owner on time [3]. That example is about pharmacovigilance reporting rather than a multi-region submission dossier specifically, but the underlying failure mode is the same one described above: a commitment with a hard deadline, tracked informally, with no system enforcing that it stays visible until it's closed. The more regions and agencies a program adds, the more of these deadlines are in flight at once — and the more expensive each dropped one becomes.
Not every RIM system markets itself around global submissions specifically, but the capabilities that actually matter for this use case are consistent across the category:
How much these capabilities actually matter shows up in the data: Gens & Associates' Regulatory Operational Excellence and World Class RIM℠ study — a January 2026 benchmark of 59 life sciences organizations — found that only one participating organization qualified as "ready and leading," while 21% fell into an "at risk" category and the remaining majority had clear capability gaps [4]. The same study found that organizations holding teams explicitly accountable for regulatory data accuracy reported a 93% data-quality confidence score, versus 50% for organizations that didn't — a difference the capabilities above are built to close, since correspondence tracking and real-time reporting only help if the underlying data can be trusted [4].
There isn't one universal path teams take to get here — most regulatory teams land on one of three general approaches before (or instead of) adopting a purpose-built RIM system. The comparison below describes these approaches generally, not specific named vendors or products, and isn't a ranking — the right fit depends on submission volume, number of active regions, and team size.
| Approach | How it typically works | Where it tends to break down |
|---|---|---|
| Spreadsheets + shared drives | One or more trackers per region; documents and correspondence stored in folders, cross-referenced manually | No single source of truth once more than one or two regions are active simultaneously; status updates require manual reconciliation |
| Bolt-on point tools | A correspondence tracker, a project-management tool, and a document repository used side by side, stitched together with manual cross-referencing | Nothing enforces the link between a commitment, the document that answers it, and the submission it belongs to; audit trail is fragmented across systems |
| Unified RIM platform | Dossier structure, correspondence, project tracking, and the underlying document repository live in one system with a shared audit trail | Requires evaluating and migrating into a single system up front; the tradeoff is less flexibility to mix best-of-breed point tools |
A handful of criteria separate a RIM system that genuinely supports multi-region planning from one that's really built around a single region and adapted after the fact:
The regulatory information management category itself is growing largely because of this exact pressure: Grand View Research projects the global RIM system market will reach $5.11 billion by 2033, growing at a 9.10% CAGR from 2026 to 2033, and attributes a meaningful share of that growth directly to sponsors "increasingly pursu[ing] approvals across multiple geographies simultaneously" as the volume of regulatory submissions worldwide climbs [2]. That's the same operational pressure described above, showing up as category-wide demand rather than an isolated complaint.
The best fit is usually a configurable, pre-validated platform scoped to a lean team's actual submission volume — not a stripped-down tier of an enterprise suite. Look for fast setup (weeks, not months), included validation, and room to add modules like eTMF or QMS later without re-platforming.
A GMP-ready RIM system maintains the same audit-trail, access-control, and validation standards GMP manufacturing already requires — automatic uneditable audit trails, role-based permissions, and continuously validated releases — applied to regulatory documents and submissions rather than manufacturing records specifically.
Most pharma and biotech teams beyond a single region use a RIM system's project-tracking and correspondence modules together — dossier status by region, agency correspondence tied to the right submission, and dependency-aware timelines — rather than a generic project-management tool alone.
Beyond core dossier and correspondence tracking: real-time cross-functional reporting, native Microsoft Office collaboration, customizable metadata, single sign-on, an included eCTD viewer, and integration paths to QMS/CTMS/ERP systems without requiring a full data migration to switch later.
Kivo's RIM module is built on the EDM (Electronic Document Management) Reference Model and supports the full range of submission types — INDs, CTAs, BLAs, NDAs, IDMPs, ANDAs, and CTIS — with 450+ pre-formatted ICH templates covering the major regions. Its correspondence and commitment tracking captures agency correspondence across email, digital files, call logs, PDFs, and scans, with smart associations that automatically update a submission project as an expected reply comes in — the specific capability that keeps a global submissions plan from depending on someone's memory of which inbox a clarification landed in. Real-time reporting with scheduled email delivery gives Clinical, Quality, and Commercial stakeholders a current status view without a manual request to Regulatory. Kivo deliberately doesn't include eCTD publishing itself — it prepares submission-ready packages with automatic change tracking for handoff to whichever internal or external publishing partner a team already uses, avoiding both markup on a white-labeled tool and lock-in to one vendor. And because every release ships pre-validated, teams don't add a validation project every time the region list grows. You can read more on Kivo's RIM page or see how it fits alongside project tracking specifically on the Regulatory Project Management Software page.
For teams building out a broader picture of RIM before evaluating specific systems, RIM Explained: Regulatory Information Management & Systems covers the category fundamentals, and A Guide to Regulatory Submissions in the US (FDA) & EU (EMA) walks through the region-specific submission process this post assumes as background. Early-stage teams specifically weighing RIM options can also see Choosing a RIM System for an Early-Stage Biotech Pipeline for a fuller vendor comparison.